Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD

Conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia

Sex: All

Ages: 18 Years – 100 Years

Healthy volunteers: No

Enrollment: 847

Sponsor: Novartis Pharmaceuticals

Location: Novartis Investigative Site Feldkirch

Summary

This observational prospective study aims to evaluate the LDL-C change and adherence to inclisiran in combination with other lipid lowering therapies or lipid lowering treatments (LLTs) under conditions of routine clinical practice.

Eligibility Criteria

Inclusion Criteria: 1. Participants who are 18 years or older 2. Participants with hypercholesterolemia having a diagnosis of ASCVD, ASCVD RE or HeFH 3. Participants who are not at LDL-C goal as per their CV risk according to respective clinical guidelines 4. Participants who per physician's criteria need to optimize their LLT 5. Participants who provide written informed consent to participate in the study 6. Participants who initiate inclisiran under conditions per local label and have LDL-C values available at baseline or within 3 months before treatment initiation. Exclusion Criteria: 1. Participants that have received inclisiran previously 2. Participants participating in a clinical trial with investigational product 3 Participants switching from previous PCSK9 mab treatment (within 90 days prior to Index date)

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05399992). StuddyBuddy aggregates publicly available trial information.